High TLR6 Expression Status Predicts a More Favorable Prognosis after Esophagectomy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.
Yusuke SatoAkiyuki WakitaEri MaedaYushi NagakiRyohei SasamoriKohei KemuriyamaShu NozakiSatoru ItoKaori TerataKazuhiro ImaiHiroshi NanjoHaruko HiraikeYoshihiro MinamiyaPublished in: Current oncology (Toronto, Ont.) (2023)
Most so-called "beneficial bacteria" in gut microbiota are Gram-positive, and TLR6 recognizes the peptidoglycan (PGN) present in their cell walls. We hypothesized that a high TLR6 expression status predicts a more favorable prognosis after esophagectomy. We used an ESCC tissue microarray (TMA) to examine TLR6 expression status in ESCC patients and to determine whether TLR6 expression status correlates with prognosis after curative esophagectomy. We also examined whether PGN influences the cell proliferation activity of ESCC lines. Clinical ESCC samples from 177 patients tested for the expression of TLR6 were categorized as 3+ (n = 17), 2+ (n = 48), 1+ (n = 68), or 0 (n = 44). High TLR6 expression (3+ and 2+) correlated with significantly more favorable 5-year overall survival (OS) and disease-specific survival (DSS) after esophagectomy than a lower TLR6 expression (1+ and 0). Univariate and multivariate analyses showed that TLR6 expression status is an independent prognostic factor that affects 5-year OS. PGN significantly inhibited the cell proliferation activity of ESCC lines. This is the first study to show that high TLR6 expression status predicts a more favorable prognosis in locally advanced thoracic ESCC patients after curative esophagectomy. PGN released from "beneficial bacteria" seems to have potential to inhibit the cell proliferation activity of ESCC.
Keyphrases
- poor prognosis
- toll like receptor
- inflammatory response
- prognostic factors
- cell proliferation
- immune response
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- binding protein
- long non coding rna
- nuclear factor
- squamous cell carcinoma
- locally advanced
- cell cycle
- spinal cord injury
- climate change
- lymph node
- patient reported outcomes
- cell therapy
- mesenchymal stem cells
- neoadjuvant chemotherapy
- gram negative
- double blind
- patient reported
- pi k akt
- data analysis